Merck & Co [MRK] vs Amgen [AMGN] Detailed Stock Comparison
Merck & Co
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Merck & Co wins in 15 metrics, Amgen wins in 5 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Merck & Co | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.73 | 27.44 | Merck & Co |
| Price-to-Book Ratio | 4.30 | 26.10 | Merck & Co |
| Debt-to-Equity Ratio | 71.99 | 924.46 | Merck & Co |
| PEG Ratio | 8.79 | 14.58 | Merck & Co |
| EV/EBITDA | 8.00 | 13.39 | Merck & Co |
| Profit Margin (TTM) | 25.79% | 17.39% | Merck & Co |
| Operating Margin (TTM) | 36.61% | 28.73% | Merck & Co |
| EBITDA Margin (TTM) | 36.61% | 28.73% | Merck & Co |
| Return on Equity | 36.91% | 105.67% | Amgen |
| Return on Assets (TTM) | 14.62% | 7.04% | Merck & Co |
| Free Cash Flow (TTM) | $18.10B | $10.39B | Merck & Co |
| Dividend Yield | 3.01% | 3.20% | Amgen |
| 1-Year Return | -29.04% | -9.77% | Amgen |
| Price-to-Sales Ratio (TTM) | 3.26 | 4.75 | Merck & Co |
| Enterprise Value | $233.17B | $210.58B | Merck & Co |
| EV/Revenue Ratio | 3.67 | 6.17 | Merck & Co |
| Gross Profit Margin (TTM) | 77.98% | 63.58% | Merck & Co |
| Revenue per Share (TTM) | $25 | $63 | Amgen |
| Earnings per Share (Diluted) | $6.49 | $10.98 | Amgen |
| Beta (Stock Volatility) | 0.40 | 0.48 | Merck & Co |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Merck & Co vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Merck & Co | -1.06% | -2.66% | 3.27% | -4.05% | -17.38% | -17.57% |
| Amgen | -0.72% | -2.54% | 7.94% | 3.59% | 6.11% | 16.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Merck & Co | -29.04% | -6.48% | 5.74% | 47.80% | 145.13% | 179.58% |
| Amgen | -9.77% | 22.38% | 25.21% | 74.90% | 438.74% | 268.02% |
Performance & Financial Health Analysis: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $207.49B | $162.01B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 12,483,860 | 1,842,602 |
| 90 Day Avg. Volume | 16,084,237 | 2,429,634 |
| Last Close | $81.75 | $301.37 |
| 52 Week Range | $73.31 - $123.94 | $253.30 - $340.89 |
| % from 52W High | -34.04% | -11.59% |
| All-Time High | $134.63 (Jun 24, 2024) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -39.28% | -13.11% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.09% |
| Quarterly Earnings Growth | -0.19% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.17% |
| Operating Margin (TTM) | 0.37% | 0.29% |
| Return on Equity (TTM) | 0.37% | 1.06% |
| Debt to Equity (MRQ) | 71.99 | 924.46 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.21 | $11.54 |
| Cash per Share (MRQ) | $3.68 | $16.38 |
| Operating Cash Flow (TTM) | $22.75B | $12.19B |
| Levered Free Cash Flow (TTM) | $17.12B | $13.09B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.01% | 3.20% |
| Last 12-Month Dividend | $2.39 | $9.26 |
Valuation & Enterprise Metrics Analysis: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.73 | 27.44 |
| Forward P/E | 8.79 | 14.58 |
| PEG Ratio | 8.79 | 14.58 |
| Price to Sales (TTM) | 3.26 | 4.75 |
| Price to Book (MRQ) | 4.30 | 26.10 |
| Market Capitalization | ||
| Market Capitalization | $207.49B | $162.01B |
| Enterprise Value | $233.17B | $210.58B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.67 | 6.17 |
| Enterprise to EBITDA | 8.00 | 13.39 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.48 |
| Book Value per Share (MRQ) | $19.21 | $11.54 |
Financial Statements Comparison: Merck & Co vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Revenue/Sales | $15.53B | $8.15B |
| Cost of Goods Sold | $3.42B | $2.97B |
| Gross Profit | $12.11B | $5.18B |
| Research & Development | $3.62B | $1.49B |
| Operating Income (EBIT) | $5.94B | $1.18B |
| EBITDA | $7.38B | $4.08B |
| Pre-Tax Income | $5.90B | $1.97B |
| Income Tax | $818.00M | $243.00M |
| Net Income (Profit) | $5.09B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Cash & Equivalents | $8.63B | $8.81B |
| Total Current Assets | $35.50B | $26.93B |
| Total Current Liabilities | $25.17B | $23.01B |
| Long-Term Debt | $33.48B | $54.01B |
| Total Shareholders Equity | $48.40B | $6.21B |
| Retained Earnings | $66.10B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Operating Cash Flow | $6.30B | $1.71B |
| Capital Expenditures | N/A | $-411.00M |
| Free Cash Flow | $1.17B | $980.00M |
| Debt Repayment | $-2.50B | $-2.50B |
| Common Stock Repurchase | $-1.16B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MRK | AMGN |
|---|---|---|
| Shares Short | 28.77M | 14.70M |
| Short Ratio | 1.61 | 5.46 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 12,483,860 | 1,842,602 |
| Average Daily Volume (90 Day) | 16,084,237 | 2,429,634 |
| Shares Outstanding | 2.53B | 537.00M |
| Float Shares | 2.51B | 536.32M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.81% | 0.84% |
Dividend Analysis & Yield Comparison: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Last 12-Month Dividend | $2.39 | $9.26 |
| Last 12-Month Dividend Yield | 3.01% | 3.20% |
| 3-Year Avg Annual Dividend | $2.77 | $8.72 |
| 3-Year Avg Dividend Yield | 0.71% | 0.79% |
| 3-Year Total Dividends | $8.31 | $26.16 |
| Ex-Dividend Date | Mar 17, 2025 | May 16, 2025 |